FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 270 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem November 2, 2022 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa March 10, 2020 COVID-19: “It could take months to build research up again” July 1, 2020 Load more HOT NEWS FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a... EMA Recommends Extension of Indications for Niraparib For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease